---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009704"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2024-07-09T23:59:59+00:00"
generated_at: "2026-05-31T22:33:35.374933+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# ReShape Lifesciences announces reverse merger with Vyome Therapeutics and asset sale for $5.16M

## Summary
- Vyome stockholders will own 88.9% of combined company; ReShape stockholders to own 11.1%.
- ReShape sells substantially all assets to Ninjour (Biorad Medisys affiliate) for $5.16M cash; Merger closes immediately after.
- Series C Preferred liquidation preference reduced from $26.2M to at most $1M or 20% of asset sale price or excess net cash.
- Up to $7.3M in concurrent financing includes $5.8M common stock at 30% discount to post-merger valuation.
- CEO Paul Hickey receives severance increase to 18 months base salary and 4% fully diluted shares.

## SEC filing metadata
- accession: 0001558370-24-009704
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2024-07-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000155837024009704/0001558370-24-009704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000155837024009704/rsls-20240708x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009704
- JSON: https://secwatch.observer/filing/0001558370-24-009704.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009704.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.